Balanced news tone
News Sentiment
EDIT sentiment intelligence
Editas Medicine Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
50
Balanced news tone
63 relevant articles
Price is moving more forcefully than the current news tone suggests.
82/100 classification confidence.
directly relevant articles
high-authority source matches
-10.7% over one week, +30.4% over four weeks, trend active, and below fair value.
Editas Medicine stock holds the line as pipeline work continues.
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Primary event
Market update
82/100 classification
One-week reaction
-10.7%
Price reacting lower
Trend fit
Trend active
30.4% over four weeks
Fair value
-23.3%
Below fair value
Value support
Sentiment Mix
Positive, neutral, negative
Positive
5
Neutral
50
Negative
8
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Market source
Direct company coverage
Why Is Editas (EDIT) Down 12.4% Since Last Earnings Report?
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 04 Jun 2026 07:00
- Source
- Market source
Motley Fool
Direct company coverage
CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026?
- Tone
- Positive 58/100
- Event
- Market update
- Published
- 31 May 2026 16:31
- Source
- Motley Fool
GlobeNewswire
Direct company coverage
Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 May 2026 20:01
- Source
- GlobeNewswire
Seeking Alpha
Direct company coverage
Editas Medicine: Resetting Pipeline Just To Be Second To Market Again (NASDAQ:EDIT)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 May 2026 07:00
- Source
- Seeking Alpha
MT Newswires
Direct company coverage
Editas Medicine Prices Public Offering of Shares, Warrants
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 May 2026 14:44
- Source
- MT Newswires
MT Newswires
Direct company coverage
Editas Medicine Proposes Public Stock Offering; Shares Fall Pre-Bell
- Tone
- Negative 30/100
- Event
- Market update
- Published
- 26 May 2026 10:38
- Source
- MT Newswires
GlobeNewswire
Direct company coverage
Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society Congress
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 May 2026 10:01
- Source
- GlobeNewswire
GlobeNewswire
Direct company coverage
Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 May 2026 07:00
- Source
- GlobeNewswire
GlobeNewswire
Direct company coverage
Editas Medicine Announces Proposed Public Offering
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 May 2026 07:00
- Source
- GlobeNewswire
Stock Titan
Direct company coverage
Editas Medicine (NASDAQ: EDIT) halts sales under TD Cowen ATM prospectus
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 May 2026 07:00
- Source
- Stock Titan
Stock Titan
Direct company coverage
Editas offering links warrant window to cholesterol trial results
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 26 May 2026 07:00
- Source
- Stock Titan
Investing.com
Direct company coverage
Editas Medicine stock tumbles on stock offering announcement
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 May 2026 07:00
- Source
- Investing.com
Investing.com
Direct company coverage
Editas Medicine launches public offering of stock and warrants
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 May 2026 07:00
- Source
- Investing.com
simplywall.st
Industry context
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
MT Newswires
Direct company coverage
Editas Medicine Lead Therapy Cuts LDL Cholesterol by 90% in Preclinical Study
- Tone
- Negative 42/100
- Event
- Market update
- Published
- 14 May 2026 10:40
- Source
- MT Newswires
Investing.com
Direct company coverage
Editas Medicine presents preclinical data on EDIT-401 therapy
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 May 2026 07:00
- Source
- Investing.com
simplywall.st
Direct company coverage
Analyst Forecasts Just Became More Bearish On Editas Medicine, Inc. (NASDAQ:EDIT)
- Tone
- Negative 34/100
- Event
- Analyst action
- Published
- 14 May 2026 07:00
- Source
- simplywall.st
Market source
Industry context
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
Market source
Direct company coverage
Some Analysts Just Cut Their Editas Medicine, Inc. (NASDAQ:EDIT) Estimates
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 11 May 2026 07:00
- Source
- Market source
simplywall.st
Industry context
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Market source
Industry context
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
simplywall.st
Direct company coverage
Earnings Update: Editas Medicine, Inc. (NASDAQ:EDIT) Just Reported And Analysts Are Boosting Their Estimates
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 08 May 2026 07:00
- Source
- simplywall.st
Market source
Industry context
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Market source
Industry context
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
Market source
Direct company coverage
Editas (EDIT) Up 3.8% Since Last Earnings Report: Can It Continue?
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 08 Apr 2026 07:00
- Source
- Market source
TradingView
Industry context
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Mar 2026 07:00
- Source
- TradingView
GlobeNewswire
Direct company coverage
Editas Medicine Announces U.S. Patent and Trademark Office
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Mar 2026 07:00
- Source
- GlobeNewswire
Stock Titan
Direct company coverage
A key U.S. CRISPR patent fight swings again toward Editas partner Broad
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Mar 2026 07:00
- Source
- Stock Titan
IndexBox
Direct company coverage
Editas Medicine (EDIT) Stock: 5-Year Valuation Drop & Recent Pipeline Challenges - News and Statistics
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Mar 2026 07:00
- Source
- IndexBox
The Motley Fool
Direct company coverage
Is Editas Medicine Going to $0?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Mar 2026 07:00
- Source
- The Motley Fool